Sugi Predict

Sugi Predict / Compounds / SCHEMBL650608

SCHEMBL650608

SCHEMBL650608

N#CC(CN1CC(NS(=O)(=O)c2ccccc2)Cc2cc(Cl)ccc21)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FNTA P49354 1/20 0.51
▸ FNTB P49356 1/20 0.51
▸ HDAC8 Q9BY41 1/20 0.43
▸ UCHL1 P09936 6/20 0.39
▸ USP30 Q70CQ3 6/20 0.39
▸ CTSB P07858 3/20 0.39
▸ CTSK P43235 3/20 0.39
▸ CTSS P25774 2/20 0.39
▸ CTSC P53634 2/20 0.39
▸ CTSL P07711 1/20 0.39
▸ HTT P42858 1/20 0.37
▸ HTR1A P08908 4/20 0.37
▸ HTR7 P34969 4/20 0.37
▸ ALDH1A1 P00352 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ TBXA2R P21731 2/20 0.35
▸ THRB P10828 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL651258 0.81 FNTA (0.55) FNTAFNTBHDAC8HTTHTR1A
SCHEMBL651202 0.80 FNTA (0.52) FNTAFNTBHDAC8HTTHTR1A
SCHEMBL648802 0.80 FNTA (0.57) FNTAFNTBHDAC8UCHL1USP30
SCHEMBL651338 0.79 FNTA (0.49) FNTAFNTBHDAC8UCHL1USP30
SCHEMBL651578 0.78 FNTA (0.62) FNTAFNTBHDAC8HTTTHRB
SCHEMBL651608 0.78 FNTA (0.52) FNTAFNTBHDAC8HTTHTR1A
SCHEMBL649319 0.78 FNTA (0.48) FNTAFNTBHDAC8HTTHTR1A
SCHEMBL650207 0.77 FNTA (0.61) FNTAFNTBHDAC8HTTHTR1A
SCHEMBL648923 0.77 FNTA (0.47) FNTAFNTBHDAC8HTTHTR1A
SCHEMBL651452 0.77 FNTA (0.67) FNTAFNTBHDAC8HTTHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7884113-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-08 — — US claimed
US-20080194625-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2008-08-14 — — US claimed
US-20050014786-A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY 2005-01-20 — — US claimed
US-8119808-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-21 — — US disclosed
US-20110104315-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2011-05-05 — — US disclosed
US-7884113-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-08 — — US disclosed
US-20080194625-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2008-08-14 — — US disclosed
US-20050014786-A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY 2005-01-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110104315-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, OPRL1 FNTA 1368/4885FNTB 2071/4885HDAC8 2618/4885
US-20050014786-A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators CNR2, CNR1, OPRL1 FNTA 1368/4885FNTB 2071/4885HDAC8 2618/4885
US-20080194625-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, OPRL1 FNTA 1368/4885FNTB 2071/4885HDAC8 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.